A

Aldeyra Therapeutics
D

ALDX

4.29000
USD
0.30
(7.52%)
مغلق
حجم التداول
34,342
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
256,952,073
أصول ذات صلة
A
AMRN
0.025
(0.15%)
16.665 USD
B
BLDP
0.08500
(5.07%)
1.76000 USD
C
CAPR
0.140
(1.41%)
10.090 USD
C
CLRB
-0.04000
(-0.84%)
4.71000 USD
E
ESCA
0.430
(2.99%)
14.790 USD
G
GERN
0.02500
(1.78%)
1.43000 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
H
HALO
0.120
(0.22%)
53.960 USD
I
IONS
-0.450
(-1.03%)
43.190 USD
NVS
NVS
-1.350
(-1.09%)
122.490 USD
O
OPK
0.01500
(1.12%)
1.36000 USD
S
SLDB
0.14500
(2.97%)
5.02000 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
C
CBIO
0.410
(2.64%)
15.935 USD
المزيد
الأخبار المقالات

العنوان: Aldeyra Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.